Exact Sciences Announces Groundbreaking Liver Cancer Detection Test with 7x Greater Sensitivity Than Standard of Care
ByAinvest
Friday, Nov 7, 2025 8:03 am ET1min read
EXAS--
Exact Sciences Corp. announced breakthrough results from the ALTUS study, demonstrating superior early detection of liver cancer with its Oncoguard Liver blood test. The study found that the test delivered seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) compared to the standard of care. The ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet